Essentially, the non-inferiority margin is the maximum clinically acceptable extent to which the new drug can be less effective than the existing one. Typically, in diabetes trials, the US Food and ...
In an accompanying editorial, Peter A McCullough, MD, and colleagues criticized the study’s methodology. 2 “The method of computation of the non-inferiority margin and the revision of this statistical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback